NASDAQ:RDNT - RadNet Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.43 +0.37 (+3.07 %)
(As of 04/24/2019 07:42 AM ET)
Previous Close$12.06
Today's Range$12.08 - $12.49
52-Week Range$9.97 - $16.54
Volume282,073 shs
Average Volume248,694 shs
Market Capitalization$622.38 million
P/E Ratio18.83
Dividend YieldN/A
Beta1.18
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. As of December 31, 2017, it operated 297 facilities directly or indirectly through joint ventures with hospitals in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDNT
CUSIPN/A
Phone310-478-7808

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$975.15 million
Cash Flow$2.2641 per share
Book Value$4.10 per share

Profitability

Net Income$32.24 million

Miscellaneous

Employees7,869
Market Cap$622.38 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

RadNet (NASDAQ:RDNT) Frequently Asked Questions

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How were RadNet's earnings last quarter?

RadNet Inc. (NASDAQ:RDNT) issued its quarterly earnings data on Thursday, March, 14th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.41. The medical research company had revenue of $257.21 million for the quarter, compared to the consensus estimate of $248.21 million. RadNet had a return on equity of 27.51% and a net margin of 3.31%. The company's quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.15) earnings per share. View RadNet's Earnings History.

When is RadNet's next earnings date?

RadNet is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for RadNet.

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2019 earnings guidance on Thursday, March, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.05-1.1 billion, compared to the consensus revenue estimate of $1.03 billion.

What price target have analysts set for RDNT?

1 analysts have issued 1-year price targets for RadNet's shares. Their predictions range from $17.50 to $17.50. On average, they anticipate RadNet's stock price to reach $17.50 in the next year. This suggests a possible upside of 40.8% from the stock's current price. View Analyst Price Targets for RadNet.

What is the consensus analysts' recommendation for RadNet?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet.

Has RadNet been receiving favorable news coverage?

News stories about RDNT stock have been trending somewhat negative on Wednesday, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. RadNet earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near future.

Who are some of RadNet's key competitors?

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), UnitedHealth Group (UNH), Adobe (ADBE), Rigel Pharmaceuticals (RIGL), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Synergy Pharmaceuticals (SGYP) and Visa (V).

Who are RadNet's key executives?

RadNet's management team includes the folowing people:
  • Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
  • Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
  • Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division

Who are RadNet's major shareholders?

RadNet's stock is owned by many different of institutional and retail investors. Top institutional investors include Dalton Greiner Hartman Maher & Co. (2.39%), Eqis Capital Management Inc. (0.18%), Strs Ohio (0.10%), Tibra Equities Europe Ltd (0.06%) and Financial Gravity Wealth Inc. (0.01%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Lawrence L Levitt, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock, Norman R Hames, Sandy Nyholm Kaminsky and Stephen M Forthuber. View Institutional Ownership Trends for RadNet.

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc. and Strs Ohio. Company insiders that have sold RadNet company stock in the last year include David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Michael L Md Sherman and Norman R Hames. View Insider Buying and Selling for RadNet.

Which institutional investors are buying RadNet stock?

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Tibra Equities Europe Ltd and Financial Gravity Wealth Inc.. View Insider Buying and Selling for RadNet.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $12.43.

How big of a company is RadNet?

RadNet has a market capitalization of $622.38 million and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe.

What is RadNet's official website?

The official website for RadNet is http://www.radnet.com.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]


MarketBeat Community Rating for RadNet (NASDAQ RDNT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Featured Article: Preferred Stock

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel